SL de Haas

Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant

Petra Hoever, SL de Haas, Julia Winkler et al. · Clinical Pharmacology & Therapeutics · 2010 · 101 citations

Medicine, Pharmacokinetics, Pharmacology +13

The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A 2,3 selective agonist, in comparison with lorazepam in healthy volunteers

SL de Haas, JAJ Schmitt, AF Cohen et al. · Journal of Psychopharmacology · 2008 · 67 citations

Medicine, Pharmacokinetics, Pharmacology +17

804 ORAL Evaluation of Plasma VEGFA as a Potential Predictive Pan-tumour Biomarker for Bevacizumab

Gordon C. Jayson, SL de Haas, Paul Delmar et al. · European Journal of Cancer · 2011 · 38 citations

Medicine, Cancer Biology, Oncology +16

Abstract S5-03: Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer

Nadia Harbeck, Oleg Gluz, Matthias Christgen et al. · Cancer Research · 2016 · 29 citations

Medicine, Pharmacology, Pharmacotherapy +17

Abstract P2-16-04: Plasma Biomarker Analyses in the AVADO Phase III Randomized Study of First-Line Bevacizumab + Docetaxel in Patients with Human Epidermal Growth Factor Receptor (HER) 2-Negative Metastatic Breast Cancer

D.W. Miles, SL de Haas, Luc Dirix et al. · Cancer Research · 2010 · 26 citations

Medicine, Oncology, Pharmacology +17